Antimicrobial resistance is fast becoming a global concern as incidents of antibiotic resistance are occurring in different parts of the world, straining the existing stock of antibiotic drugs. Many natural antimicrobial peptides can kill bacteria and fungi but they are often toxic and possessing long sequences. In addition, they also share sequence similarity to human proteins, causing potential complications if used as drugs. We have designed short amphiphilic peptides which are far easier to synthesise and which do not share common sequences to any native ones, thus avoiding potential biological problems. In addition, rational design has enabled us to tune their potency against toxicity, thus enhancing their selectivity. Patient filing has progressed well, and we expect to have approval from both EU and USA in 2017.